Boston Scientific Corporation

BSXNYSEHealthcare● Active

$48.65

+$0.10(+0.21%)

Market Cap$72.3B

P/E Ratio—

52W High$109.5

52W Low$47.17

Avg Volume18.4M

Open$48.05

Beta0.56

Overview

Boston Scientific Corporation (BSX) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

BSX · free cash flow · updated Jun 8, 2026

Core FCF metrics

BSX · FCF · TTM · margin & CAGR

Free cash flow was $3.66B for FY2025 (fiscal year ending 2025-12-31), up 38.3% year-over-year The FCF margin was 18.2%. Five-year CAGR stands at +26.4%.

FY2025 Free Cash Flow$3.66B▲ +38.3% YoY

Trailing 12M (TTM)$3.44Btrailing 4 quarters sum

FCF Margin18.2%$3.66B ÷ revenue

3-Year CAGR+58.8%FY2022 → FY2025

5-Year CAGR+26.4%FY2020 → FY2025

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

BSX · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest$4.53B(876M)$3.66B▲ +38.3%18.2%

FY2024$3.44B(790M)$2.65B▲ +55.3%15.8%

FY2023$2.50B(800M)$1.70B▲ +86.3%12.0%

FY2022$1.53B(612M)$914.0M▼ 30.5%7.2%

FY2021$1.87B(554M)$1.32B▲ +16.3%11.1%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

BSX · P/FCF · FCF yield · FCF per share

Boston Scientific Corporation (BSX) trades at a FCF yield of 4.75% and a price-to-free-cash-flow ratio of 20.9x. FCF per share stands at $2.33, calculated using trailing twelve-month FCF divided by basic weighted-average shares outstanding.

FCF Yield (TTM)

4.75%

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

$2.33

TTM FCF ÷ Shares Outstanding

Price / FCF

x20.9

Share Price ÷ FCF per Share

EV / FCF (TTM)

x23.8

Enterprise Value basis

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

BSX · cash flow statement · operating / investing / financing

For FY2025, Boston Scientific Corporation generated $4.53B in operating cash flow and spent 876M in capital expenditures, yielding $3.66B in free cash flow.

Operating Activities

+$4.53B

Cash from core business operations

2025-12-31

Investing Activities

−$2.64B

CapEx, acquisitions & investments

2025-12-31

Financing Activities

−$395.0M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF ($4.53B) − |CapEx| (876M) = FCF ($3.66B)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

BSX vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Boston Scientific CorporationYOU

BSX

$3.66B+38.3%18.2%

19%

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Boston Scientific Corporation (BSX) reported free cash flow of $3.66B for FY2025 (fiscal year ending 2025-12-31), up 38.3% year-over-year. The FCF margin was 18.2%.

Based on available data, Boston Scientific Corporation has maintained positive free cash flow for at least 14 fiscal year(s). FCF peaked at $3.66B in FY2025. The 5-year CAGR stands at +26.4%.

Boston Scientific Corporation's FCF yield is 4.75% and price-to-FCF ratio is 20.9x for FY2025, based on the latest available data.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

BSX free cash flow · 8 questions

Boston Scientific Corporation free cash flow was $3.66B for FY2025, up 38.3% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $3.44B.

BSX free cash flowBSX FCFBSX FCF 2025BSX free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Boston Scientific Corporation · Boston Scientific Corporation SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026